A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

BACKGROUND The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women. METHODS The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor-positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. This analysis compares the two groups assigned to receive letrozole initially with the two groups assigned to receive tamoxifen initially; events and follow-up in the sequential-treatment groups were included up to the time that treatments were switched. RESULTS A total of 8010 women with data that could be assessed were enrolled, 4003 in the letrozole group and 4007 in the tamoxifen group. After a median follow-up of 25.8 months, 351 events had occurred in the letrozole group and 428 events in the tamoxifen group, with five-year disease-free survival estimates of 84.0 percent and 81.4 percent, respectively. As compared with tamoxifen, letrozole significantly reduced the risk of an event ending a period of disease-free survival (hazard ratio, 0.81; 95 percent confidence interval, 0.70 to 0.93; P=0.003), especially the risk of distant recurrence (hazard ratio, 0.73; 95 percent confidence interval, 0.60 to 0.88; P=0.001). Thromboembolism, endometrial cancer, and vaginal bleeding were more common in the tamoxifen group. Women given letrozole had a higher incidence of skeletal and cardiac events and of hypercholesterolemia. CONCLUSIONS In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites. (ClinicalTrials.gov number, NCT00004205.)

[1]  R. Chlebowski,et al.  Meta-analysis of vascular and neoplastic events associated with tamoxifen , 2003, Journal of General Internal Medicine.

[2]  J. Cuzick,et al.  Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Roberto Orecchia,et al.  Breast cancer , 2005, The Lancet.

[5]  E. Perez,et al.  The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  T. Lash,et al.  Tamoxifen‐treated breast carcinoma patients and the risk of acute myocardial infarction and newly‐diagnosed angina , 2005, Cancer.

[7]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[8]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Lønning.  Aromatase inhibitors in breast cancer. , 2004, Endocrine-related cancer.

[10]  P. Lønning,et al.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.

[11]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[12]  M. Dowsett.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .

[13]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.

[14]  J. Cuzick,et al.  Overview of the main outcomes in breast cancer prevention trials , 2003 .

[15]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[16]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[18]  D B Evans,et al.  Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Elisaf,et al.  Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. , 2001, European journal of cancer.

[20]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Herrington,et al.  Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. , 2001, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[22]  S. Reis,et al.  Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. , 2001, Journal of the National Cancer Institute.

[23]  D. Tripathy,et al.  Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .

[24]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[25]  P. Lønning,et al.  In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  C. Osborne,et al.  Tamoxifen in the treatment of breast cancer. , 1998, The New England journal of medicine.

[27]  P. Lønning,et al.  Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. , 1996, British Journal of Cancer.

[28]  T. Powles,et al.  The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  M. Dowsett,et al.  In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  F. Alexander,et al.  Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial , 1995, BMJ.

[31]  L. Rutqvist,et al.  Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. , 1993, Journal of the National Cancer Institute.

[32]  A. Agresti.  [A Survey of Exact Inference for Contingency Tables]: Rejoinder , 1992 .

[33]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[34]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[35]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[36]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[37]  D.,et al.  Regression Models and Life-Tables , 2022 .